Lusutrombopag

Lusutrombopag is an agonist of the thrombopoietin receptor. It induces proliferation of Ba/F3 cells expressing human MPL, the gene for the thrombopoietin receptor, with an EC50 value of 84 nM but not of those expressing mouse Mpl. Lusutrombopag (0.3-10 mg/kg per day) increases the number of circulating platelets in a transgenic mouse model expressing human MPL and increases the number of megakaryocytes in the bone marrow when administered at a dose of 10 mg/kg per day. Formulations containing lusutrombopag have been used in the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo invasive procedures.Formal Name: (2E)-3-[2,6-dichloro-4-[[[4-[3-[(1S)-1-(hexyloxy)ethyl]-2-methoxyphenyl]-2-thiazolyl]amino]carbonyl]phenyl]-2-methyl-2-propenoic acid. CAS Number: 1110766-97-6. Molecular Formula: C29H32Cl2N2O5S. Formula Weight: 591.5. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMSO: 30 mg/ml. lambdamax: 218, 260, 322 nm. SMILES: ClC1=C(/C=C(C)/C(O)=O)C(Cl)=CC(C(NC2=NC(C3=CC=CC([C@H](C)OCCCCCC)=C3OC)=CS2)=O)=C1. InChi Code: InChI=1S/C29H32Cl2N2O5S/c1-5-6-7-8-12-38-18(3)20-10-9-11-21(26(20)37-4)25-16-39-29(32-25)33-27(34)19-14-23(30)22(24(31)15-19)13-17(2)28(35)36/h9-11,13-16,18H,5-8,12H2,1-4H3,(H,35,36)(H,32,33,34)/b17-13+/t18-/m0/s1. InChi Key: NOZIJMHMKORZBA-KJCUYJGMSA-N.